How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,396 results for

adhd Methylphenidate

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. (Full text)

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude (...) of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non-serious adverse events.To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non-randomised studies.In January 2016, we searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, 12 other databases

2018 Cochrane PubMed abstract

2. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. (Full text)

Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. This is an update of the original Cochrane Review published in Issue 4, 2011.Attention deficit hyperactivity disorder (ADHD) is the most prevalent of the comorbid psychiatric disorders that complicate tic disorders. Medications commonly used to treat ADHD symptoms include stimulants such as methylphenidate and amphetamine; non-stimulants, such as atomoxetine; tricyclic (...) antidepressants; and alpha agonists. Alpha agonists are also used as a treatment for tics. Due to the impact of ADHD symptoms on the child with tic disorder, treatment of ADHD is often of greater priority than the medical management of tics. However, for many decades, clinicians have been reluctant to use stimulants to treat children with ADHD and tics for fear of worsening their tics.  OBJECTIVES: To assess the effects of pharmacological treatments for ADHD in children with comorbid tic disorders on symptoms

2018 Cochrane PubMed abstract

3. Attention deficit hyperactivity disorder: diagnosis and management

this guideline into practice 51 Context 53 More information 54 Update information 55 Attention deficit hyperactivity disorder: diagnosis and management (NG87) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 62This guideline replaces CG72 and TA98. This guideline is the basis of QS39. Ov Overview erview This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children (...) , young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD. Who is it for? Healthcare professionals Commissioners and providers People with ADHD, and their families and carers Attention deficit hyperactivity disorder: diagnosis and management (NG87) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5 of 62Recommendations Recommendations People

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

4. Attention deficit hyperactivity disorder (ADHD): avoid guanfacine

hyperactivity disorder (ADHD): avoid guanfacine In children diagnosed with attention deficit hyperactivity disorder (ADHD), guanfacine has no proven efficacy in improving family and social relationships. On the other hand, it has frequent, sometimes severe, adverse effects. In practice, it is best to avoid guanfacine. The diagnosis of attention deficit hyperactivity disorder in children is based on non-specific behavioural symptoms: inattentiveness, hyperactivity and impulsiveness. The disruptive impact (...) Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Prescrire IN ENGLISH - Spotlight ''Attention deficit hyperactivity disorder (ADHD): avoid guanfacine'', 1 October 2017 {1} {1} {1} | | > > > Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Attention deficit

2017 Prescrire

5. Attentin (dexamfetamine) - attention deficit/hyperactivity disorder (ADHD)

Attentin (dexamfetamine) - attention deficit/hyperactivity disorder (ADHD) Attentin (dexamfetamine) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Attentin (dexamfetamine) Conclusion Attentin (dexamfetamine) is a CNS stimulant agent for treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. Attentin can be used second-line when response to methylphenidate is not sufficiently effective or has caused (...) been established compared to placebo and is presumably on a par with methylphenidate. However, the evidence in support thereof is based on small studies with different measures of effectiveness. Therefore, the effect of Attentin cannot be established with certainty. The long-term effects have not been investigated thoroughly. The most common adverse reactions are reduced appetite and sleeplessness. When prescribing Attentin, doctors should pay attention to cardiac events, growth and abuse potential

2017 Danish Pharmacotherapy Reviews

6. Young Children with Attention-Deficit/Hyperactivity Disorder and/or Disruptive Behavior Disorders Are More Frequently Prescribed Alpha Agonists Than Stimulants. (Abstract)

Young Children with Attention-Deficit/Hyperactivity Disorder and/or Disruptive Behavior Disorders Are More Frequently Prescribed Alpha Agonists Than Stimulants. Objective: To examine medication prescribing patterns for preschool-aged children with diagnoses of attention-deficit/hyperactivity disorder (ADHD) and/or disruptive behavior disorder (DBD). Secondary objectives included determining if prescription patterns varied by gender, insurance type, or comorbid diagnosis of autism spectrum (...) disorder (ASD). Methods: A retrospective, cross-sectional chart review was completed for children ages 2-5 years who were treated at an academic medical center between 2013 and 2016 with a diagnosis of ADHD and/or DBD. Data were analyzed by Fisher's exact and chi-square tests and Cochran-Armitage trend analysis. Results: Of the 966 children who met inclusion criteria, 343 (35.5%) were prescribed ADHD medications. For 2-, 3-, and 4-year olds, the most commonly prescribed medication was an alpha agonist

2020 Journal of Child and Adolescent Psychopharmacology

7. Attention deficit hyperactivity disorder in adults

Attention deficit hyperactivity disorder in adults Attention deficit hyperactivity disorder in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Attention deficit hyperactivity disorder in adults Last reviewed: February 2019 Last updated: October 2018 Summary A common adult disorder, thought to be persistence of childhood attention deficit hyperactivity disorder (ADHD). Prevalence of 2% to 5% in the general (...) in combination with medication. Definition Adult attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder presenting with inattentiveness, impulsivity, and hyperactivity, persisting into adulthood. Diagnosis can be made in either adulthood or childhood by 7 years of age (age limit increased in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition [DSM-5] to 12 years). Functional impairment is a criterion for diagnosis. Comorbid disorders are present in more than 75

2018 BMJ Best Practice

8. Attention deficit hyperactivity disorder in adults

Attention deficit hyperactivity disorder in adults Attention deficit hyperactivity disorder in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Attention deficit hyperactivity disorder in adults Last reviewed: February 2019 Last updated: October 2018 Summary A common adult disorder, thought to be persistence of childhood attention deficit hyperactivity disorder (ADHD). Prevalence of 2% to 5% in the general (...) in combination with medication. Definition Adult attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder presenting with inattentiveness, impulsivity, and hyperactivity, persisting into adulthood. Diagnosis can be made in either adulthood or childhood by 7 years of age (age limit increased in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition [DSM-5] to 12 years). Functional impairment is a criterion for diagnosis. Comorbid disorders are present in more than 75

2018 BMJ Best Practice

9. Can methylphenidate be used for adults with attention deficit hyperactivity disorder (ADHD)?

Can methylphenidate be used for adults with attention deficit hyperactivity disorder (ADHD)? application/msword

2017 Specialist Pharmacy Services

10. Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

2014, four systematic reviews (including pairwise meta-analyses and network meta-analyses of direct and indirect evidence), one randomized controlled trial, and one guideline have been published regarding the use of guanfacine hydrochloride extended-release (GXR) for the treatment of attention deficit-hyperactivity disorder (ADHD) in children and adolescents.All included studies reported significant improvements in subjective ADHD rating scales as well as scales in executive function when using GXR (...) Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. Guanfacine (Intuniv) for attention deficit hyperactivity disorder (Full text)

a suboptimal response to stimulants. PBS listing Authority Required (Streamlined) On 1 March 2019, guanfacine (Intuniv) was listed on the PBS as an Authority Required (Streamlined) listing. It was listed as an adjunctive treatment to stimulant medicines in patients with attention deficit hyperactivity disorder (ADHD). , To receive subsidised treatment, patients must have residual moderate to severe symptoms despite receiving a maximum tolerated dose (MTD) of dexamfetamine, methylphenidate (...) submission for guanfacine are summarised below. ADHD-RS-IV: The Attention Deficit Hyperactivity Disorder Rating Scale IV is an investigator-rated questionnaire. It consists of 18 items that measure ADHD symptoms according to DSM-IV criteria. Scores range from 0 (never) to 54 (always). A between-group minimally clinically important difference (MCID) has not been fully established, but a 30% mean total score change (or 5.2–7.7 points) has been suggested in some publications. CGI-S: For the Clinical Global

2019 National Prescribing Service Limited (Australia) PubMed abstract

12. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder Kim Boesen , Luis Carlos Saiz , Juan Erviti , Ole Jakob Storebø , Christian Gluud , Peter C Gøtzsche , Karsten Juhl Jørgensen Statistics from Altmetric.com Background Attention deficit hyperactivity disorder (ADHD) in adults is one of the most controversial diagnoses in medicine, and the use of methylphenidate is sharply rising. The Cochrane review by Epstein and colleagues about (...) The trials lasted only 1–7 weeks, and the long-term beneficial and harmful effects of methylphenidate are therefore unknown. Most adults with ADHD receive methylphenidate for substantially longer periods, and the beneficial effects may furthermore diminish over time. This was observed in the large Multimodal Treatment of Attention Deficit Hyperactivity Disorder Study in children. The short trial duration should therefore have led to additional downgrading for indirectness according to GRADE. Small trials

2017 Evidence-Based Medicine

13. Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents

, Ph.D. AHRQ Publication No. 18-EHC005-EF January 2018 ii Key Messages Purpose of Review To update a previous review by comparing strategies to diagnose, treat, and monitor children and adolescents with attention deficit hyperactivity disorder (ADHD). Key Messages • Evidence was insufficient on imaging or electroencephalogram to diagnose ADHD in children 7–17 years of age. • Little evidence adds to the 2011 report that found that methylphenidate is effective for children under age 6 with ADHD (...) . Harvard TH Chan School of Public Health Boston, MA Peter Jensen, M.D. Mayo Clinic Rochester, MN viii Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents Structured Abstract Objectives. Attention deficit hyperactivity disorder (ADHD) is a common pediatric neurobehavioral disorder often treated in the primary care setting. This systematic review updates and extends two previous Agency for Healthcare Research and Quality (AHRQ) systematic evidence reviews

2018 Effective Health Care Program (AHRQ)

14. Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. (Abstract)

Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. Objective: To examine the effectiveness of four doses of psychostimulant medication, combining extended-release methylphenidate (ER-MPH) in the morning with immediate-release MPH (IR-MPH) in the afternoon, on cognitive task performance. Method: The sample comprised 24 children (19 boys and 5 girls) who met the Diagnostic (...) and Statistical Manual of Mental Disorders, 4th Edition Text Revision (DSM-IV-TR) criteria for an autism spectrum disorder (ASD) on the Autism Diagnostic Interview-R and the Autism Diagnostic Observation Schedule, and had significant symptoms of attention-deficit/hyperactivity disorder (ADHD). This sample consisted of elementary school-age, community-based children (mean chronological age = 8.8 years, SD = 1.7; mean intelligence quotient = 85; SD = 16.8). Effects of placebo and three dose levels of ER-MPH

2020 Journal of Child and Adolescent Psychopharmacology

15. Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder

identified regarding the duration of dosage effect for methylphenidate SR for patients with attention deficit hyperactivity disorder. Tags attention deficit disorder with hyperactivity, dexamfetamine, dexedrine, dextroamphetamine, mental health, methylphenidate, ritalin, Concerta, time course Files Rapid Response Summary of Abstracts Published : September 2, 2015 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder | CADTH.ca Find the information you need Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Duration of Dosage Effect for Methylphenidate SR

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release

with ADHD should always form part of a comprehensive treatment plan that includes psychological, behavioural and educational advice and interventions. Where drug treatment is considered appropriate, the guideline recommends methylphenidate, atomoxetine and dexamfetamine, within their licensed indications, as options for the management of ADHD in children and young people. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70) © NICE 2018. All rights (...) for the management of ADHD in children and young people. Choice of drug should be guided by comorbidities, adverse effects, specific issues that may affect compliance, the potential for drug diversion or misuse, and the preferences of the child or young person or their parent or carer. The guideline recommends that healthcare professionals should consider: methylphenidate for ADHD without significant comorbidity Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release

2016 National Institute for Health and Clinical Excellence - Advice

17. The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities: A systematic review. (Abstract)

The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities: A systematic review. The effectiveness of psychostimulants, primarily methylphenidate (MPH), in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the general population of typically growing children and adolescents is well established through many Randomised Controlled Trials (RCTs).We carried out a systematic review of all (...) the RCTs in people with intellectual disabilities (ID) that assessed effectiveness of MPH on the core ADHD symptoms.We included 15 papers from 13 studies that were all on children and adolescents with ID (315 participants were on MPH and placebo respectively), 12 of which used a cross over design, and one used a parallel design. On average around 40-50% responded to MPH in the ID group whereas around 70-80% response rate is reported among the non-ID children. Because of the heterogeneity of the outcome

2019 Research in developmental disabilities

18. Changes in Sleep Problems Across Attention-Deficit/Hyperactivity Disorder Treatment: Findings from the Multimodal Treatment of Attention-Deficit/Hyperactivity Disorder Study. (Full text)

Changes in Sleep Problems Across Attention-Deficit/Hyperactivity Disorder Treatment: Findings from the Multimodal Treatment of Attention-Deficit/Hyperactivity Disorder Study. Stimulant medication and behavior therapy are efficacious for youth with attention-deficit/hyperactivity disorder (ADHD). However, research suggests that stimulants may start and/or worsen sleep problems for youth. Further, the impact of behavior therapy for ADHD on sleep is unknown. This study examined the frequency (...) of sleep problems and effects of stimulant medication, behavior therapy, and their combination on sleep problems in youth with ADHD. This study also explored the influence of dimensional baseline ratings of ADHD symptom subtype and psychiatric comorbidity on sleep outcomes.Participants were 576 children (aged 7-9 years) with ADHD-Combined type from the Multimodal Treatment of ADHD study that compared methylphenidate, behavior therapy, and their combination to community care. Before treatment, parents

2018 Journal of Child and Adolescent Psychopharmacology PubMed abstract

19. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. (Abstract)

Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. Psychostimulants are the first-line treatment in adults with attention-deficit hyperactivity disorder (ADHD). This meta-analysis aimed to evaluate the efficacy, acceptability, and tolerability of lisdexamfetamine (LDX), mixed amphetamine salts (MASs), modafinil (MDF (...) ), and methylphenidate (MPH) in comparison with placebo.We systematically searched PubMed/MEDLINE and Clinicaltrials.gov in May 2016, along with CENTRAL and EU Clinical Trials Register in February 2016, for the randomized, double-blind, placebo-controlled, parallel-group clinical trials conducted on adults diagnosed with ADHD.Substantial comorbidity, substance abuse or dependence, and nonpharmacological interventions represented grounds for exclusion. Published reports were the sole source for data extraction

2020 The Annals of pharmacotherapy

20. Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder. (Full text)

Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder. HLD200 is an evening-dosed, delayed-release and extended-release methylphenidate (DR/ER-MPH) that provides a consistent delay in initial drug release to target onset of therapeutic effect from awakening and maintain it into the evening. Building on a modeling framework established with other extended (...) a phase 3 trial of children with attention-deficit/hyperactivity disorder and simulated plasma concentration-time data. Simulations using the PK/PD model were performed for doses of 60, 80, and 100 mg of DR/ER-MPH, administered 4 to 14 hours before the classroom day.The PK/PD model predicts that DR/ER-MPH produces a clinical response from early morning into the late afternoon or evening, with increased duration of response occurring with increasing doses. Furthermore, the PK/PD model predicts

2020 Journal of Clinical Psychopharmacology PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>